malondialdehyde has been researched along with beraprost in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murata, T; Nishio, S; Umetsu, T | 1 |
| Guo, Y; Lei, W; Pan, Y; Tang, Y; Wang, J; Yang, J; Yu, H; Yu, L | 1 |
2 other study(ies) available for malondialdehyde and beraprost
| Article | Year |
|---|---|
Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Bucladesine; Calcimycin; Calcium; Calcium Radioisotopes; Cyclic AMP; Epoprostenol; In Vitro Techniques; Male; Malondialdehyde; Platelet Aggregation Inhibitors; Rats; Rats, Inbred Strains; Thrombin; Thromboxane B2 | 1989 |
Beraprost sodium protects against chronic brain injury in aluminum-overload rats.
Topics: Aluminum; Aluminum Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Damage, Chronic; Cytochrome P-450 Enzyme System; Epoprostenol; Gluconates; Hippocampus; Intramolecular Oxidoreductases; Male; Malondialdehyde; Maze Learning; Memory Disorders; Nerve Tissue Proteins; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Superoxide Dismutase | 2015 |